What Фозикард Treats: Main Uses and Benefits

Фозикард (Fosinopril) is commonly used to help with conditions characterized by periods of heightened symptoms related to cardiovascular function. The medication is applied across therapeutic domains where additional symptomatic support is needed.

The two main therapeutic areas in which Фозикард is relevant are high blood pressure (hypertension) and the symptomatic burden of heart failure.

The active ingredient, Fosinopril, is commonly used to help manage symptoms related to heightened physiological activity that interfere with daily functioning. Its use is considered relevant in conditions involving episodic or fluctuating manifestations of hypertension and heart failure. For patients, this application supports the management of symptoms that create noticeable physiological strain. This therapeutic application assists with maintaining functional stability when symptoms are more noticeable. This approach may be part of symptomatic management in settings marked by temporary physiological imbalance.

The medication contributes to easing the overall symptom burden and helps improve day-to-day comfort during symptomatic periods.

---

Quick Fact: Support for Symptoms related to heightened physiological activity (High Blood Pressure)

Regulatory References

1. NIH Bookshelf overview on Fosinopril

Who Can and Cannot Use Фозикард?

The population eligibility for Фозикард (Fosinopril sodium) is defined by official regulatory criteria that determine who is allowed to use the medicine, who is restricted, and who is absolutely prohibited.

Category	Official Regulatory Statement
Populations for whom use is contraindicated	Patients with a history of angioedema (swelling) linked to any ACE inhibitor, or those with hereditary/idiopathic angioedema.
	Pregnancy during the second and third trimesters.
	Patients with Diabetes Mellitus or renal impairment (GFR < 60) concurrently taking Aliskiren (Dual RAAS blockade).
Age-related eligibility rules	Approved for adults and for hypertensive children aged 6 to 16 years weighing over 50 kg. Use is not established for children under 6 years of age.
Physiological restrictions	Contraindicated during second and third trimesters of pregnancy. Not recommended during the first trimester and while breastfeeding.
Condition-specific restrictions	Patients with bilateral renal artery stenosis or severe volume/salt depletion require conditional use and close monitoring. Lower starting doses may be recommended for heart failure patients with moderate to severe renal dysfunction.

Фозикард Interactions with other medicines and products

This section outlines the clinically significant interactions of Фозикард (Fosinopril sodium) as documented in official government regulatory sources, based on risks of severe adverse effects or altered drug exposure.

---

Formal Contraindicated Combinations

Interacting Agent	Restriction and Context
Aliskiren	Contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 mL/min/1.73 m^2).
Sacubitril/Valsartan	Co-administration is contraindicated. A mandatory 36-hour separation is required between the last dose of either medication and the initiation of the other.

---

Pharmacodynamic and Exposure-Altering Interactions

Фозикард may alter or be altered by the following substance classes:

• Agents that Increase Serum Potassium: Co-administration with Potassium-sparing diuretics, Potassium supplements, or Heparin may lead to hyperkalemia (high potassium levels).
• NSAIDs: Non-Steroidal Anti-Inflammatory Drugs, including COX-2 inhibitors, may lead to deterioration of renal function and attenuate the antihypertensive effect. This risk is noted to be greater in elderly or volume-depleted patients.
• Lithium: Concomitant use with Lithium has been reported to cause increased serum lithium levels and potential toxicity.
• Antacids: Antacids containing aluminum or magnesium hydroxide can reduce the absorption of the active metabolite. If co-administration is necessary, Фозикард and the antacid should be separated by 2 hours.
• Food/Supplements: No interaction with food is documented; however, Potassium-containing salt substitutes are cited as a risk for hyperkalemia.

Фозикард (Fosinopril) functions as an angiotensin-converting enzyme (ACE) inhibitor following its conversion to the active metabolite, fosinoprilat.

This activation occurs through hydrolysis, primarily within the liver and gastrointestinal mucosa.

Fosinoprilat exerts its effect by competitively binding to the active site of the ACE enzyme, which is a zinc-containing metalloprotease also known as kininase II. By inhibiting this enzyme, fosinoprilat sterically blocks the conversion of the decapeptide angiotensin I into the potent vasoconstrictor, angiotensin II. This action reduces the systemic and local concentrations of angiotensin II, thereby modulating the renin-angiotensin-aldosterone system (RAAS), leading to diminished vasoconstrictive, aldosterone-secreting, and sympathetic nervous system effects.

Simultaneously, the inhibition of kininase II impedes the degradation of the peptide bradykinin. The resultant increase in local and systemic bradykinin levels contributes to the dilation of peripheral and pulmonary vasculature. The collective consequence of these molecular events is a reduction in total peripheral vascular resistance.

Фозикард is administered through the oral route using tablet formulations. The standardized approach to its use involves a process of dose titration for long-term management, where the amount taken is adjusted based on the patient’s measured response.

For the initial management of hypertension or heart failure in adults, the typical starting dose is 10 mg once daily. The usual maintenance dosage generally falls within the range of 20 mg to 40 mg per day, which is also administered once daily. In certain cases of hypertension, the maximum daily amount is 80 mg. The daily dose may be divided and taken twice per day if the therapeutic effect is observed to diminish toward the end of the 24-hour dosing interval.

Administration is subject to specific procedural constraints. To ensure proper absorption, Фозикард must be taken at a separate time from antacids containing aluminum or magnesium, requiring a 2-hour separation between the doses. Furthermore, if a dose is missed, the patient should skip that dose and return to the regular schedule if it is almost time for the next dose; doses must never be doubled. For specific populations, no initial dose adjustment is typically required for patients with renal impairment due to the drug's dual elimination pathway. Use in children 6 to 16 years old with hypertension is weight-based, with usual starting doses of 5 mg to 10 mg once daily for those over 50 kg.

Фозикард (Fosinopril): Overview of Available Research Evidence

---

Evidence for Use in High Blood Pressure (Hypertension)

Research studied Фозикард for high blood pressure, focusing on general adult patient populations. Studies examined measurements related to systemic pressure and outcomes related to systemic or functional imbalance. The evidence base includes clinical recognition; this indicates that this therapeutic class has a history of use in medical practice for exploring long-term patterns of pressure change.

The research explored measurements related to blood pressure and outcomes related to functional stability during the study periods. However, the available documentation often provides limited information for long-term outcomes regarding the durability of these patterns. Additionally, specific details about study design, such as the exact sample sizes were modest or the duration of patient follow-up, are often not explicitly detailed in the general summaries of this evidence.

---

Evidence for Use in Symptomatic Burden of Heart Failure

Фозикард was studied for use in patients facing heart failure, particularly focusing on conditions characterized by fluctuating or episodic manifestations where symptomatic support was evaluated in research. Research was applied in studies examining patient-reported experiences to evaluate the overall symptom burden and outcomes reflecting daily functioning or activity level. These studies were primarily conducted during periods of increased symptom activity.

Findings describe patterns related to the overall symptom burden observed in the specific populations studied. A key point is that this evidence primarily describes support for outcomes related to physical discomfort or symptoms. The research currently summarized does not explicitly focus on hard clinical endpoints often studied in heart failure, such as hospitalization rates or survival data. Follow-up durations were limited in some reports, which restricts insights into long-term effects are not fully established related to this condition.

Key Studies & References Fosinopril - NIH Bookshelf (StatPearls)

Common questions about Фозикард (FAQ)

---

Q: Does Фозикард make you sleepy or affect driving?

Official regulatory information advises caution regarding certain activities. The product label states that due to potential effects like dizziness or sleepiness (somnolence), Фозикард may temporarily impair the ability to drive, use tools, or operate machinery. Patients are generally advised to understand how this medication affects them before attempting such activities.

---

Q: Can I drink alcohol while taking Фозикард?

Official regulatory documents clearly state that concurrent use of alcohol is typically advised against or discouraged while taking this medication. This is because alcohol may potentially increase the risk of certain side effects, specifically those related to central nervous system depression, when combined with this product.

---

Q: What is the correct storage temperature for Фозикард tablets?

According to the official product information, Фозикард tablets must be stored at controlled room temperature. This is generally defined as being between 20 C and 25 C (or 68 F to 77 F). Proper storage conditions are essential for maintaining the product's quality.

---

Q: Can children under 12 years old use Фозикард?

Official regulatory texts indicate that the medication is generally authorized for use only in adults and adolescents aged 12 years and older. The approved labeling does not establish a dosage or sufficient safety information for pediatric patients younger than 12 years old.

---

Q: What should I do if I miss a dose of Фозикард?

The official product information advises that the missed dose may be taken as soon as it is remembered. However, if it is already close to the time for the next scheduled dose, the general guidance suggests skipping the missed dose entirely and continuing with the regular schedule. It is explicitly stated that two doses should not be taken to compensate for a missed one.

How to Store and Dispose of Fosinopril Sodium (Фозикард)

The storage of Fosinopril Sodium tablets must adhere strictly to regulated conditions to preserve the product's stability and integrity.

---

Official Storage Requirements

• Temperature: Store at Controlled Room Temperature, 20°C to 25°C (68°F to 77°F). Brief excursions up to 30°C are permitted.
• Protection: The container must be kept tightly closed to protect the tablets from moisture and stored away from excess heat (such as a bathroom).
• Container: The product is required to be dispensed in a tight, light-resistant container with a child-resistant closure.
• Child Safety: All medication must be kept out of the sight and reach of children at all times.

---

Disposal Instructions

Unused or expired Fosinopril tablets should be disposed of by taking them to an authorized drug take-back program. If a take-back program is unavailable, the medication must be mixed with an undesirable substance, sealed in a bag, and placed in the household trash. Do not flush Fosinopril tablets down the toilet or pour them down a drain.